Navigation Links
ThermoGenesis Reports Fourth Quarter and Fiscal 2009 Results
Date:9/9/2009

ng charges in the quarter also included $0.2 million related to the release and launch of the Company's Res-Q(TM) 60 BMC ("Res-Q") System, and $0.6 million of excess and aged surgical wound care inventory reserved in connection with the planned divesture of the CryoSeal product line. The Company also recorded $0.2 of severance charges during the quarter.

The company ended fiscal 2009 with $15.6 million in cash and short-term investments, compared with $17.7 million at the end of the third quarter of fiscal 2009 and $25.3 million at the end of fiscal 2008.

"While we have been able to manage our ongoing operating expenses, the non-recurring costs during the quarter reflect the impact of our key strategic initiatives that are focused on both ensuring a high level of quality and expanding the market for our offerings," said J. Melville Engle, Chief Executive Officer.

"We have continued to experience success with our quality initiatives through enhanced internal processes and increased communications with our key suppliers and customers. We also realized significant progress in our initiative to outsource the manufacturing of our devices and expect to complete this transition for our BioArchive and ThermoLine devices by the end of fiscal 2010.

"Our market expansion objectives," he continued, "are being realized with the initial market experience for our devices to process stem cells from bone marrow for orthopedic procedures--the MXP and Res-Q, which was formally launched at the end of July. Both devices have demonstrated solid results in terms of cell recovery and ease of use. Celling Technologies, our distributor for the products, is optimistic about the near-term market expansion opportunities through both adding new centers and entering new geographies. In addition, we will be looking to expand new indications beyond orthopedics for the Res-Q, as well as adding new distributors outside the U
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... 7 Biocept, Inc. ("Biocept"), an emerging leader in biotechnology, ... "We are pleased to welcome Bruce to ... we move into our next stage of development," said Stephen ... been a practicing Certified Public Accountant since 1986.  He is ...
... that a new market research report is available in ... R&D: Technology and Market 2010-2025 ... – how will biobanking develop and contribute to healthcare? ... you want to know the prospects for biobanking in ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) ... Officer of BioMarin, will host a conference ... at 5:00 p.m. ET to discuss third ... Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay ...
Cached Biology Technology:Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 2Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 3Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 4Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 5Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 6Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 7Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 8Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 9Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 10Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025 11BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET 2
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... to their offering. One major trend ... biometric systems. Multimodal biometric systems utilize more than one ...
(Date:12/10/2014)... Baptist Medical Center today announced plans for a new medical ... $50 million capital project is part of a larger capital ... The medical education building will be located in the ... 525@vine in Wake Forest Innovation Quarter. Construction will begin immediately ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... Huntington,s disease, a mutated protein in the body becomes toxic ... small region adjacent to the mutated segment plays a major ... the National Institutes of Health show that very slight changes ... mice. Researchers do not fully understand why the protein ...
... the atomic structure of new anti-cancer agents has enabled a ... capable of halting a common type of drug-resistant lung cancer. ... 24/31 issue of the journal Nature , the researchers ... to the drugs Iressa and Tarceva were stymied by a ...
... Microbiology has awarded one of its international professorships to ... department at Kansas State University. The society has ... will be a visiting professor at the Universidad Nacional ... his Fusarium Laboratory Workshop in March 2010. The ...
Cached Biology News:Small changes in protein chemistry play large role in Huntington's disease 2Small changes in protein chemistry play large role in Huntington's disease 3Research yields new agent for some drug-resistant non-small cell lung cancers 2Research yields new agent for some drug-resistant non-small cell lung cancers 3
ROCK-1 (cleaved) Monoclonal Ab 100 ug purified mouse monoclonal antibody. Clone# 12M03. Reacts with human. Tested in Western blot analysis....
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
Mouse monoclonal [CAT-1] to Chloramphenicol Acetyltransferase ( Abpromise for all tested applications)....
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: